China: China FDA Solicits Comments On Resolving The Backlog Of Drug Applications

The China Food and Drug Administration ("CFDA") recently published a draft circular to address the backlog of drug applications. The Circular Regarding Several Draft Policy Opinions to Accelerate the Resolution of the Backlog of Drug Applications Issued by the CFDA (CFDA Circular [2015] No. 140, the "No. 140 Circular"), which is open for public comment through August 15, 2015, proposes ten policies to reduce the backlog of the drug applications and expedite the approval process for certain types of drugs. The No. 140 Circular also proposes changing the approval system for bioequivalence studies. 

The No. 140 Circular appears to be a response to the State Council's criticism of the CFDA earlier this summer. In May and June, the State Council conducted a nationwide review regarding the implementation of significant policies. According to the resulting summary report, nine departments (including the CFDA) were criticized and ordered to conduct rectifications within a specific time. Specifically, the main criticism of the CFDA was that its drug review and approval process was inefficient. The CFDA's first response to this criticism came with its circular regarding the commencement of a self-inspection project for drug clinical trial data. Published on July 22, 2015, this Circular Regarding the Launch of Self-Inspection of Drug Clinical Trial Data (CFDA Circular [2015] No. 117, the "No. 117 Circular") requested that the applicants of 1622 drug submissions submit a self-inspection report to the Center for Food and Drug Inspection of CFDA. The No. 117 Circular further provided that, if the self inspection revealed inaccurate or incomplete clinical study data, the applicant should withdraw the application voluntarily by August 25, 2015. 

The CFDA's latest response to the State Council's criticism has taken the form of the No. 140 Circular, which provides the following implementation rules: 

  • Raises the technical review standards for generic drugs: If the originator drug has been marketed in China, generic applications will be approved only if their quality and efficacy is consistent with that of the originator; if the originator has not yet marketed in China, any approved generic drugs must pass a consistency evaluation within three years after going to market in China. If the generic drug fails to pass the consistency evaluation within the three years, the corresponding drug approval will be revoked. 
  • Imposes severe penalties on false data submitted in drug applications: If any false data is found in the clinical trial, the relevant authority will blacklist the relevant applicant, clinical trial site, contract research organization or the relevant responsible person. In addition, such applicant will be debarred from drug applications for three years, and such responsible person will be debarred from participating drug clinical materials for ten years. 
  • Rejects drug applications that fail to meet requirements: The No. 140 Circular reiterates that applicants must complete the self-inspection in accordance with the No. 117 Circular by August 25, 2015. An applicant can withdraw its applications voluntarily if it finds any major defects during the self-inspection. Meanwhile, the CFDA can disapprove the application directly if it finds any major defects during the technical review process. 
  • Strictly controls the approval of drug applications for changes in dosage form, acid or alkaline forms, or route of administration: Applicants seeking approval for such changes must present evidence of innovation, safety and efficacy, and thus an obvious advantage when compared with the original dosage form. Proposed changes that do not present such obvious advantages will not be approved by the CFDA. 
  • Optimizes the review and approval for clinical trial applications: The review of clinical trial and bioequivalence study applications will focus on the measures to assure the subjects' safety. The CFDA will disapprove any application with major defects. If no major defects are found, the CFDA can issue a conditional approval, with the applicant making any necessary improvements in its research plan based on the technical guideline. Bioequivalence studies will no longer require affirmative prior approval and will instead only require notification to the CFDA. If the CFDA raises no objection within thirty days from the applicant's notification, the applicant may initiate the bioequivalence study. 
  • Launches centralized review of the same type of drug applications in the backlog: For drug applications of the same type accepted by the authorities, the CFDA will launch a centralized review based on the same review criteria. 
  • Accelerates the approval process for drugs that address urgent clinical needs: Pediatric drug applications, as well as drug applications that have been submitted by the drug administrations in the EU and the US simultaneously, will be subject to fast track approval. Furthermore, the National Health Family Planning Commission and the Ministry of Industry and Information Technology will propose a list of drugs for which there is an urgent clinical need or shortage. The CFDA will then provide additional comments regarding the eligibility of fast track approvals for such drugs to seek approvals from the State Council. 
  • Addresses pending applications from the 2008 centralized review: Any applications still pending from the 2008 centralized review will be returned to the applicants if the applicants cannot resolve the issues regarding safety, efficiency, quality control, or authenticity of the research materials. 
  • Discourage generic companies from redundant applications. The CFDA will compile a Catalogue of Generic Drugs subject to Restricted Review and Approval. This Catalogue will serve as guidance to streamline generic applications. Generics whose supplies are greater than demand, which have an unclear therapeutic effect or safety profile, or whose formulations are insensible will be placed on the Catalogue.
  • Regulates the drug registration appeal procedure: If the applicant disagrees with the CDE's technical review decision, it can submit an appeal application. Thereafter, the CDE will invite experts, the applicant, and the technical review officials to a technical review meeting and the relevant technical appeal conclusion will be published to the public. 

In summary, the release of the No. 117 Circular and the No. 140 Circular are believed to be CFDA's proposed rectification scheme that will be submitted to the State Council to address the drug application backlog issue and thus improve the efficiency of the drug review system. Companies who have pending drug applications in China are advised to review their pending drug dossiers and pay close attention to such policies.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions